Study on Supplement of Intravenous Ferric Derisomaltose to Prevent Anemia and Improve the Quality of Life in Obese Patients With Iron Deficiency.

Condition(s) studied

Investigational drug(s) / intervention(s)

Iron Isomaltoside injection: Patients in the isomaltan iron group received intravenous isomaltan iron dissolved in 250 ml of normal saline 3 days prior to surgery. The patients' iron requirements were calculated using a simplified scale, with a maximum single dose of 20 mg/kg. If the dose was insufficient in a single administration, a second infusion was required every other week. The placebo group received an equal volume of 0.9% normal saline. Simplified scale: Hemoglobin (g/L) patient weight \<50kg 50-70kg \>70kg ≥100 500mg 1000mg 1500mg \<100 500mg 1500mg 2000mg

Physiological saline solution (as placebo): At the same time point, the same dose of physiological saline was infused as the experimental group.

Study summary

This study aimed to explore the effects of preoperative intravenous isomaltose iron supplementation versus placebo on postoperative Hb improvement, prevention of postoperative anemia, and improvement in quality of life in patients undergoing bariatric surgery.

Eligibility

Primary outcome measure(s)

• changes in Hb concentration compared to baseline — 3 months post-surgery,

Trial sites (1)

More China-Japan Friendship Hospital trials in Japan

Other trials for the same condition